No black box warning on record for Retevmo

As of the latest FDA labeling reviewed, Retevmo (SELPERCATINIB) does not carry a black box warning. Standard warnings and precautions still apply — see the full Retevmo medicine page for the complete safety profile.

Other warnings & precautions

5 WARNINGS AND PRECAUTIONS Hepatotoxicity : Monitor ALT and AST prior to initiating RETEVMO, every 2 weeks during the first 3 months, then monthly thereafter and as clinically indicated. Withhold, reduce the dose, or permanently discontinue RETEVMO based on severity. ( 2.5 , 5.1 ) Interstitial Lung Disease (ILD)/Pneumonitis : Monitor for new or worsening pulmonary symptoms. Withhold, reduce the do

No black box warning on record for Retevmo

Other warnings & precautions

5 WARNINGS AND PRECAUTIONS Hepatotoxicity : Monitor ALT and AST prior to initiating RETEVMO, every 2 weeks during the first 3 months, then monthly thereafter and as clinically indicated. Withhold, reduce the dose, or permanently discontinue RETEVMO based on severity. ( 2.5 , 5.1 ) Interstitial Lung Disease (ILD)/Pneumonitis : Monitor for new or worsening pulmonary symptoms. Withhold, reduce the do

Retevmo Black Box Warning

No black box warning on record for Retevmo

Other warnings & precautions

Retevmo Black Box Warning

No black box warning on record for Retevmo

Other warnings & precautions